Literature DB >> 12849754

Transient attenuation of protein kinase Cepsilon can terminate a chronic hyperalgesic state in the rat.

C A Parada1, J J Yeh, D B Reichling, J D Levine.   

Abstract

Recently we demonstrated that a single 3-day episode of carrageenan-induced acute cutaneous inflammation can create a chronic state of increased susceptibility to inflammatory hyperalgesia. In this latent "primed" state, although there is no ongoing hyperalgesia, the hyperalgesic response to subsequent challenges with inflammatory agent (prostaglandin E2; PGE2) is greatly enhanced. Furthermore, the PGE2-induced hyperalgesia in primed skin was found to require activity of the epsilon isozyme of protein kinase C (PKCepsilon), a second messenger that is not required for PGE2-induced hyperalgesia in control animals. In the present study we tested the hypothesis that activity of PKCepsilon not only plays a critical role in the expression of primed PGE2-induced hyperalgesia, but also in the development and maintenance of the primed state itself. Antisense oligodeoxynucleotide was employed to produce a decrease in PKCepsilon in the nerve, verified by Western blot analysis. PKCepsilon was found to be essential both for the development of carrageenan-induced hyperalgesic priming, as well as for the maintenance of the primed state. Furthermore, hyperalgesic priming could be induced by an agonist of PKCepsilon (pseudo-receptor octapeptide for activated PKCepsilon) at a dose that itself causes no hyperalgesia. The finding that transient inhibition of PKCepsilon can not only prevent the development of priming, but can also terminate a fully developed state of priming suggests the possibility that selective targeting PKCepsilon might be an effective new strategy in the treatment of chronic inflammatory pain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12849754     DOI: 10.1016/s0306-4522(03)00267-7

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  64 in total

1.  Hyperalgesic priming is restricted to isolectin B4-positive nociceptors.

Authors:  E K Joseph; J D Levine
Journal:  Neuroscience       Date:  2010-05-10       Impact factor: 3.590

2.  Defective translocation of PKCepsilon in EtOH-induced inhibition of Mg2+ accumulation in rat hepatocytes.

Authors:  Lisa M Torres; Bocena Konopnika; Liliana N Berti-Mattera; Carole Liedtke; Andrea Romani
Journal:  Alcohol Clin Exp Res       Date:  2010-06-25       Impact factor: 3.455

3.  Alcohol consumption enhances antiretroviral painful peripheral neuropathy by mitochondrial mechanisms.

Authors:  Luiz F Ferrari; Jon D Levine
Journal:  Eur J Neurosci       Date:  2010-08-19       Impact factor: 3.386

4.  Eccentric exercise induces chronic alterations in musculoskeletal nociception in the rat.

Authors:  Pedro Alvarez; Jon D Levine; Paul G Green
Journal:  Eur J Neurosci       Date:  2010-08-19       Impact factor: 3.386

5.  Role of Kv4.3 in Vibration-Induced Muscle Pain in the Rat.

Authors:  Lindsay B Conner; Pedro Alvarez; Oliver Bogen; Jon D Levine
Journal:  J Pain       Date:  2015-12-22       Impact factor: 5.820

6.  Regulation of Expression of Hyperalgesic Priming by Estrogen Receptor α in the Rat.

Authors:  Luiz F Ferrari; Dionéia Araldi; Jon D Levine
Journal:  J Pain       Date:  2017-01-09       Impact factor: 5.820

7.  Distinct terminal and cell body mechanisms in the nociceptor mediate hyperalgesic priming.

Authors:  Luiz F Ferrari; Dioneia Araldi; Jon D Levine
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

8.  The fundamental unit of pain is the cell.

Authors:  David B Reichling; Paul G Green; Jon D Levine
Journal:  Pain       Date:  2013-12       Impact factor: 6.961

9.  Mechanisms mediating vibration-induced chronic musculoskeletal pain analyzed in the rat.

Authors:  Olayinka A Dina; Elizabeth K Joseph; Jon D Levine; Paul G Green
Journal:  J Pain       Date:  2009-12-03       Impact factor: 5.820

10.  Opioid-Induced Hyperalgesic Priming in Single Nociceptors.

Authors:  Eugen V Khomula; Dionéia Araldi; Ivan J M Bonet; Jon D Levine
Journal:  J Neurosci       Date:  2020-11-17       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.